NTS Medical ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 11.2% 22.8% 12.8% 15.8%  
Credit score (0-100)  0 23 4 17 11  
Credit rating  N/A BB B BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  0.0 17.6 -15.7 -39.1 -79.6  
EBITDA  0.0 17.6 -15.7 -39.1 -79.6  
EBIT  0.0 17.6 -15.7 -39.1 -79.6  
Pre-tax profit (PTP)  0.0 17.0 -20.5 -41.1 -80.9  
Net earnings  0.0 13.3 -20.5 -28.5 -84.3  
Pre-tax profit without non-rec. items  0.0 17.0 -20.5 -41.1 -80.9  

 
See the entire income statement

Balance sheet (kDKK) 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 63.3 42.7 1.7 -82.6  
Interest-bearing liabilities  0.0 61.2 0.0 48.9 61.9  
Balance sheet total (assets)  0.0 140 83.3 64.1 18.9  

Net Debt  0.0 53.2 -43.9 1.6 54.5  
 
See the entire balance sheet

Volume 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 17.6 -15.7 -39.1 -79.6  
Gross profit growth  0.0% 0.0% 0.0% -148.3% -103.6%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 140 83 64 19  
Balance sheet change%  0.0% 0.0% -40.6% -23.0% -70.5%  
Added value  0.0 17.6 -15.7 -39.1 -79.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 -1.0 -2.0 -3.0  

Profitability 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 12.5% -14.1% -53.0% -96.1%  
ROI %  0.0% 14.1% -18.8% -83.7% -141.4%  
ROE %  0.0% 21.0% -38.7% -128.2% -817.1%  

Solidity 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  0.0% 45.1% 51.3% 2.7% -81.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 302.6% 278.7% -4.1% -68.5%  
Gearing %  0.0% 96.7% 0.0% 2,831.0% -74.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1.8% 15.6% 8.4% 2.4%  

Liquidity 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  0.0 1.8 2.1 1.0 0.2  
Current Ratio  0.0 1.8 2.1 1.0 0.2  
Cash and cash equivalent  0.0 8.1 43.9 47.3 7.4  

Capital use efficiency 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 63.3 42.7 1.7 -82.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0